ログイン
言語:

WEKO3
  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学部学科区分一覧
  2. 医学部・医学系研究科・医学部附属病院
  1. 資料タイプ一覧
  2. 学術雑誌論文
  1. 鳥取大学の刊行物
  2. Yonago Acta Medica
  3. 62
  4. 1

Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness

https://repository.lib.tottori-u.ac.jp/records/4773
https://repository.lib.tottori-u.ac.jp/records/4773
c2af5c15-0659-4bb4-85cb-95e53dbd7f17
名前 / ファイル ライセンス アクション
yam62(1)_85.pdf yam62(1)_85.pdf (1.2 MB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2019-06-17
タイトル
タイトル Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness
言語 en
言語
言語 eng
キーワード
主題 cetuximab
キーワード
主題 EGFR siRNA
キーワード
主題 KRAS
キーワード
主題 nonsmall cell lung cancer
キーワード
言語 en
主題 cetuximab
キーワード
言語 en
主題 EGFR siRNA
キーワード
言語 en
主題 KRAS
キーワード
言語 en
主題 nonsmall cell lung cancer
資源タイプ
資源タイプ journal article
著者 Miyake, Naomi

× Miyake, Naomi

WEKO 17106

Miyake, Naomi
Search repository
Chikumi, Hiroki

× Chikumi, Hiroki

WEKO 17107

Chikumi, Hiroki
Search repository
Yamaguchi, Kosuke

× Yamaguchi, Kosuke

WEKO 17108

Yamaguchi, Kosuke
Search repository
Takata, Miyako

× Takata, Miyako

WEKO 17109

Takata, Miyako
Search repository
Takata, Miki

× Takata, Miki

WEKO 3616
研究者総覧鳥取大学 100000925

Takata, Miki
ja-Kana タカタ, ミキ
en Takata, Miki
Search repository
Okada, Kensaku

× Okada, Kensaku

WEKO 17110

Okada, Kensaku
Search repository
Kitaura, Tsuyoshi

× Kitaura, Tsuyoshi

WEKO 17111

Kitaura, Tsuyoshi
Search repository
Nakamoto, Masaki

× Nakamoto, Masaki

WEKO 4846
e-Rad 70379642
研究者総覧鳥取大学 100000202

Nakamoto, Masaki
ja-Kana ナカモト, マサキ
en Nakamoto, Masaki
Search repository
Yamasaki, Akira

× Yamasaki, Akira

WEKO 4358
e-Rad 70325009
研究者総覧鳥取大学 100000447

Yamasaki, Akira
ja-Kana ヤマサキ, アキラ
en Yamasaki, Akira
Search repository
Miyake, Naomi

× Miyake, Naomi

WEKO 17112

en Miyake, Naomi
Search repository
Chikumi, Hiroki

× Chikumi, Hiroki

WEKO 17113

en Chikumi, Hiroki
Search repository
Yamaguchi, Kosuke

× Yamaguchi, Kosuke

WEKO 17114

en Yamaguchi, Kosuke
Search repository
Takata, Miyako

× Takata, Miyako

WEKO 17115

en Takata, Miyako
Search repository
Okada, Kensaku

× Okada, Kensaku

WEKO 17116

en Okada, Kensaku
Search repository
Kitaura, Tsuyoshi

× Kitaura, Tsuyoshi

WEKO 17117

en Kitaura, Tsuyoshi
Search repository
著者所属
値 Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine
著者所属
値 Division of Infectious Diseases, Tottori University Hospital
著者所属
値 Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine
著者所属
値 Department of Pathobiological Science and Technology, School of Health Science, Tottori University Faculty of Medicine
著者所属
値 Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine
著者所属
値 Division of Infectious Diseases, Tottori University Hospital
著者所属
値 Division of Infectious Diseases, Tottori University Hospital
著者所属
値 Division of Infectious Diseases, Tottori University Hospital
著者所属
値 Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine
著者所属（英）
言語 en
値 Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine
著者所属（英）
言語 en
値 Division of Infectious Diseases, Tottori University Hospital
著者所属（英）
言語 en
値 Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine
著者所属（英）
言語 en
値 Department of Pathobiological Science and Technology, School of Health Science, Tottori University Faculty of Medicine
著者所属（英）
言語 en
値 Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine
著者所属（英）
言語 en
値 Division of Infectious Diseases, Tottori University Hospital
著者所属（英）
言語 en
値 Division of Infectious Diseases, Tottori University Hospital
著者所属（英）
言語 en
値 Division of Infectious Diseases, Tottori University Hospital
著者所属（英）
言語 en
値 Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine
抄録
内容記述タイプ Other
内容記述 [Background] The epidermal growth factor receptor (EGFR) is a therapeutic target for patients with non-small cell lung cancer (NSCLC). Cetuximab is an anti-EGFR monoclonal antibody that inhibits EGFR signaling and proliferation of colorectal cancer and head and neck cancers. Since only few NSCLC patients benefit from cetuximab therapy, we evaluated a novel combination treatment using cetuximab and EGFR small interfering RNA (siRNA) to strongly suppress EGFR signaling and searched for a biomarker in NSCLC cell lines harboring wild-type EGFR. [Methods] Alterations in EGFR and its downstream genes in five NSCLC cell lines (A549, Lu99, 86-2, Sq19 and Ma10) were assessed through sequencing. The protein expression levels of these molecules were assessed through western blotting. The effect of combination treatment was determined through cell proliferation assay, caspase-3/7 assay, invasion assay, and migration assay. [Results] All cell lines were harboring wild-type EGFR, whereas KRAS, PTEN, TP53 and TP53 were mutated in A549 and Lu99; Lu99 and Sq19; Lu99, 86-2, Sq19 and Ma10; and A549, 86-2, and Sq19 cell lines, respectively. PTEN was not expressed in Sq19, and LKB1 was not expressed in both A549 and Sq19. TP53 was not expressed in both A549 and Lu99. The combination of cetuximab and EGFR siRNA significantly suppressed cell proliferation in 86-2, Sq19 and Ma10, which express wild-type KRAS. It induced apoptosis in A549, 86-2 and Ma10 cells, which express wild type PTEN. The combination treatment had no effect either on cell invasion nor migration in all cell lines. [Conclusion] EGFR targeted therapy using the combination of cetuximab and EGFR siRNA is effective in NSCLC cell lines harboring wild-type EGFR. Wild-type KRAS may act as a potential biomarker for response to combination treatment by the induction of apoptosis in cells with wild-type PTEN.
書誌情報 Yonago Acta Medica
en : Yonago Acta Medica

巻 62, 号 1, p. 85-93, 発行日 2019-03-28
出版者
出版者 Tottori University Medical Press
ISSN
収録物識別子タイプ ISSN
収録物識別子 05135710
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA00892882
DOI
関連タイプ isIdenticalTo
識別子タイプ DOI
関連識別子 10.33160/yam.2019.03.012
権利
権利情報 Yonago Acta medica　編集委員会
情報源
関連名称 Yonago Acta Medica. 2019, 62(1), 85-93
関連サイト
識別子タイプ URI
関連識別子 https://www.jstage.jst.go.jp/article/yam/62/1/62_2019.03.012/_article/-char/en
関連名称 https://www.jstage.jst.go.jp/article/yam/62/1/62_2019.03.012/_article/-char/en
関連サイト
識別子タイプ URI
関連識別子 http://www.lib.tottori-u.ac.jp/yam/yam/yam62-1/62-1contents.html
関連名称 http://www.lib.tottori-u.ac.jp/yam/yam/yam62-1/62-1contents.html
著者版フラグ
出版タイプ VoR
EISSN
値 1346-8049
戻る
0
views
See details
Views

Versions

Ver.1 2023-08-02 07:17:31.340503
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm

Powered by WEKO3

Powered by WEKO3